image sourced from original article at Researchers at the Technion have developed a new artificial intelligence tool that could significantly change how doctors decide whether breast cancer patients need chemotherapy. Each year, about 5,000 people in Israel, 300,000 in the United States, and roughly 2.3 million worldwide are diagnosed with the disease, underscoring the global impact of treatment decisions.
Current methods used to estimate the risk of cancer recurrence and the potential benefit of chemotherapy rely on genomic tests. While helpful, these tests are expensive, take weeks to deliver results, and are not widely accessible. Their predictive accuracy is also limited, leaving room for improvement.
The newly developed artificial intelligence system aims to provide a more accessible, faster, and potentially more accurate way to guide chemotherapy decisions, offering hope for more personalized and efficient care.
